News
Article
Acquisition includes company’s inflammatory disease medicines.
Amgen revealed in a company press release that it has officially finished its purchase of Horizon Therapeutics for an approximate value of $27.8 billion. According to the company, the acquisition includes:
"Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses," said Robert A. Bradway, chairman, CEO, Amgen. "We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases."
Reference: AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC. Amgen. October 6, 2023. Accessed October 6, 2023. https://www.amgen.com/newsroom/press-releases/2023/10/amgen-completes-acquisition-of-horizon-therapeutics-plc
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.